Editor
Video of a T-cell attacking a cancer cell.
February 15, 2017 (YouTube)
Immunotherapy Promising for Slowing Progression of ALS
June 4, 2018 (HealthDay News)
Positive results seen for autologous infusions of expanded regulatory T lymphocytes in three patients
MONDAY, June 4, 2018 (HealthDay News) —...
New Study Finds that Lowering Cholesterol Improves Immunotherapy
May 19, 2018 (Medical News Today)
This study was published in the Journal of Experimental Medicine. It discovered that when cholesterol levels are decreased, cancer...
Combo of Chemo & Immunotherapy Determined Feasible in Metastatic Bladder Cancer
April 11, 2018 (HealthDay News)
One-year overall survival of 61 percent for gemcitabine and cisplatin plus ipilimumab
Gemcitabine and cisplatin (GC) plus ipilimumab is associated with...
The Goal of Armored CAR T Cells
Dr. Renier Brentjens, MD, PhD from the Memorial Sloan Kettering Cancer Center, discusses the goal of armored CAR T-cells. He talks about how the...
Cancer: How a novel gel could halt its return
March 23, 2018 (Medical News Today)
A biodegradable gel has been developed to stop the recurrence of cancer. Scientists at the Dana-Farber Cancer Institute in...
VIDEO: CAR T-cells for CLL
February 19, 2018 (YouTube) Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia.
Speaking from the American Society of Hematology (ASH) 2017...
VIDEO: The Impact of CAR T-Cell Therapy on ALL
February 15, 2018 (YouTube)
Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of CAR T-cell therapy for patients with...
Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma
Published on February 13, 2018
Sattva S. Neelapu, MD, discusses the safety and practical implications for axi-cel (KTE-C19) as part of the ZUMA-1 trial, as...
Omaha Firefighter Receives CAR T-Cell Therapy – Nebraska Medicine
Diagnosed with lymphoma, Nick Howe was out of options before he tried CAR T-Cell therapy at Nebraska Medicine. Today, the Omaha firefighter is in...
